**Supplementary Materials**

**Supplementary material 01**. Association between 3D/3D+ and 30-day mortality. Adjusted odds ratio (aOR) and corresponding statistical significance according to multivariable logistic regression models.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Model 1** |  | **Model 2** |  | **Model 3** |  | **Model 4** |
|  | **aOR (95% CI)** | **p-value** | **aOR (95% CI)** | **p-value** | **aOR (95% CI)** | **p-value** | **aOR (95% CI)** |
| **3D Baseline component** |  |  |  |  | - |  | - |
| No frailty (3D 0) | 1 |  | 1 |  |  |  |  |
| Mild frailty (3D 1) | 0.89 (0.24-3.30) | 0.866 | 0.72 (0.17-3.00) | 0.655 |  |  |  |
| Moderate frailty (3D 2) | 2.57 (0.90-7.28) | 0.076 | 1.48 (0.47-4.67) | 0.503 |  |  |  |
| Severe frailty (3D 3) | 2.93 (1.03-8.35) | 0.044 | 1.27 (0.39-4.20) | 0.691 |  |  |  |
| **3D+ Current component** |  |  |  |  |  |  |  |
| **Functional decline** |  |  |  |  |  |  |  |
| No |  |  | 1 |  | 1 |  | 1 |
| Yes, acute |  |  | 4.49 (1.65-12.19) | 0.003 | 4.64 (1.72-12.51) | 0.002 | 4.25 (1.59-11.37) |
| Yes, progressive |  |  | 5.00 (1.73-14.49) | 0.003 | 5.19 (1.81-14.90) | 0.002 | 5.01 (1.75-14.31) |
| **Delirium** |  |  |  |  |  |  |  |
| No |  |  | 1 |  | 1 |  | 1 |
| Yes, hyperactive |  |  | 6.06 (1.92-19.11) | 0.002 | 6.41 (2.09-19.67) | 0.001 | 6.01 (2.01-17.99) |
| Yes, hypoactive |  |  | 6.64 (2.98-14.80) | <0.001 | 6.97 (3.19-15.24) | <0.001 | 6.44 (3.01-13.79) |
| **24-hour treatment at home is feasible** |  |  |  |  |  |  | - |
| Yes |  |  | 1 |  | 1 |  |  |
| No |  |  | 0.60 (0.24-1.52) | 0.283 | 0.58 (0.20-1.44) | 0.237 |  |
| **Medication explains the reason for consultation** |  |  |  |  |  |  | - |
| No |  |  | 1 |  | 1 |  |  |
| Yes |  |  | 0.58 (0.21-1.61) | 0.299 | 0.54 (0.20-1.44) | 0.220 |  |
| Area under the curve ROC (95% CI) | **0.62 (0.54-0.69)** |  | **0.82 (0.76-0.88)** |  | **0.81 (0.75-0.87)** |  | **0.80 (0.74-0.87)** |

**Supplementary material 02.** Discriminative abilityof 3D+, CFS and ISAR. Area under the curve ROC (95%CI).

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | | **AUC**  **(95%CI)** | | | |
| **Return to ED within 72 hours** | | | | |
| 3D+ (delirium - functional decline) | | 0.64 (0.51-0.77) | | | |
| CFS | | 0.72 (0.54-0.90) | | | |
| ISAR | | 0.52 (0.39-0.65) | | | |
| **Return to ED within 30 days** | |  | | | |
| 3D+ (delirium - functional decline) | | 0.45 (0.37-0.53) | | | |
| CFS | | 0.45 (0.36-0.54) | | | |
| ISAR | | 0.46 (0.37-0.55) | | | |
| **30-day mortality** | |  | | | |
| 3D+ (delirium - functional decline) | | 0.80 (0.73-0.86) | | | |
| CFS | | 0.67 (0.59-0.76) | | | |
| ISAR | | 0.58 (0.50-0.67) | | | |
| **Some adverse outcome at 30 days** | | | |
| 3D+ (delirium - functional decline) | | 0.66 (0.60-0.73) | | | |
| CFS | | 0.58 (0.51-0.65) | | | |
| ISAR | | 0.54 (0.47-0.61) | | | |
| **6-month mortality** |  | |
| 3+ (delirium - functional decline) | | 0.71 (0.64-0.77) | | | |
| CFS | | 0.67 (0.61-0.75) | | | |
| ISAR | | 0.61 (0.54-0.68) | | | |
| **12-month mortality** |  | |
| 3D+ (delirium - functional decline) | | 0.66 (0.60-0.72) | | | |
| CFS | | 0.69 (0.63-0.75) | | | |
| ISAR | | 0.60 (0.53-0.67) | | | |

AUC: Area under the curve ROC (95%CI)